49 related articles for article (PubMed ID: 16490579)
1. Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin.
Braeckman RA; Stirtan WG; Soni PN
Clin Drug Investig; 2015 Jan; 35(1):45-51. PubMed ID: 25471740
[TBL] [Abstract][Full Text] [Related]
2. Combination of fenofibrate plus low-dose nicotinic acid added to statin treatment in type 2 diabetes: An open-label, crossover study.
Vega GL; Vajja M; Palacio N; Caterp NB; Grundy SM
Curr Ther Res Clin Exp; 2006 Sep; 67(5):321-33. PubMed ID: 24678105
[TBL] [Abstract][Full Text] [Related]
3. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin.
Lee JE; van Heeswijk R; Alves K; Smith F; Garg V
Antimicrob Agents Chemother; 2011 Oct; 55(10):4569-74. PubMed ID: 21825288
[TBL] [Abstract][Full Text] [Related]
4. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease.
Undas A; Celinska-Löwenhoff M; Löwenhoff T; Szczeklik A
J Thromb Haemost; 2006 May; 4(5):1029-36. PubMed ID: 16689755
[TBL] [Abstract][Full Text] [Related]
5. Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy.
Tarantino N; Santoro F; De Gennaro L; Correale M; Guastafierro F; Gaglione A; Di Biase M; Brunetti ND
Vasc Health Risk Manag; 2017; 13():29-41. PubMed ID: 28243111
[TBL] [Abstract][Full Text] [Related]
6. Statin use and the risk of Clostridium difficile in academic medical centres.
Motzkus-Feagans CA; Pakyz A; Polk R; Gambassi G; Lapane KL
Gut; 2012 Nov; 61(11):1538-42. PubMed ID: 22442166
[TBL] [Abstract][Full Text] [Related]
7. Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH.
Goldberg RB; Bittner VA; Dunbar RL; Fleg JL; Grunberger G; Guyton JR; Leiter LA; McBride R; Robinson JG; Simmons DL; Wysham C; Xu P; Boden WE
Am J Med; 2016 Jul; 129(7):753.e13-22. PubMed ID: 27036394
[TBL] [Abstract][Full Text] [Related]
8. Impact of Vancomycin-Induced Changes in the Intestinal Microbiota on the Pharmacokinetics of Simvastatin.
Sunwoo J; Ji SC; Kim AH; Yu KS; Cho JY; Jang IJ; Lee S
Clin Transl Sci; 2020 Jul; 13(4):752-760. PubMed ID: 32058642
[TBL] [Abstract][Full Text] [Related]
9. Clinical Analysis of Atorvastatin Calcium, Fenofibrate, and Acipimox in the Treatment of Hypertriglyceridemia-induced Acute Pancreatitis.
Tong L; Xu S; Chen Z; Gao J; Huang Q; Lin X; Lin S; Lin Z; Zheng Y
Altern Ther Health Med; 2024 Mar; ():. PubMed ID: 38518139
[TBL] [Abstract][Full Text] [Related]
10. Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.
Tziomalos K; Athyros VG
Int J Nanomedicine; 2006; 1(2):129-47. PubMed ID: 17722529
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacokinetic Drug Interaction Potential of MenoAct851 in Adult, Female Healthy Volunteers.
Thangavel Mahalingam V; Kaliappan I; Rajappan Chandra SK; George M; Ramasamy MK; Sabarathinam S; Govind Prasad D
Curr Ther Res Clin Exp; 2021; 94():100619. PubMed ID: 33393940
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic interaction between regorafenib and atorvastatin in rats.
Szkutnik-Fiedler D; Szałek E; Otto F; Czyrski A; Karaźniewicz-Łada M; Wolc A; Grześkowiak E; Lewandowski K; Karbownik A
Pharmacol Rep; 2024 Apr; ():. PubMed ID: 38632186
[TBL] [Abstract][Full Text] [Related]
13. Hypophosphatemic effect of niacin extended release in ischemic kidney disease.
Yasmeen G; Dawani ML; Mahboob T
EXCLI J; 2015; 14():1095-103. PubMed ID: 26933406
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Targeted Delivery of Simvastatin and Niacin to Macrophages Using Mannan-Grafted Magnetite Nanoparticles.
Rastegari B; Ghamar Talepoor A; Khosropanah S; Doroudchi M
ACS Omega; 2024 Jan; 9(1):658-674. PubMed ID: 38222576
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics of single-dose oral atorvastatin and its metabolites support therapeutic use in cockatiels (Nymphicus hollandicus).
Mitchell M; Guzman DS; Knych H; Beaufrère H
Am J Vet Res; 2024 Apr; ():1-7. PubMed ID: 38626797
[TBL] [Abstract][Full Text] [Related]
16. New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies.
Foucher C; Aubonnet P; Reichert P; Berli M; Schaeffer A; Calvo Vargas CG; Lochocka A; Belenky D; Koch HF;
Cardiovasc Ther; 2015 Dec; 33(6):329-37. PubMed ID: 26227087
[TBL] [Abstract][Full Text] [Related]
17. Fibrates in combination with statins in the management of dyslipidemia.
Jacobson TA; Zimmerman FH
J Clin Hypertens (Greenwich); 2006 Jan; 8(1):35-41; quiz 42-3. PubMed ID: 16407687
[TBL] [Abstract][Full Text] [Related]
18. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT
Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
